Funding
The following is a non-exhaustive list of current and recent grants and contracts awarded to CVD faculty, in the following broad categories: Federal contracts, Federal cooperative agreements, Federal grants, Federal training grants and non-Federal grants and contracts. Further information on our NIH awards can be obtained from the NIH RePORT system.
Federal Contracts
Karen L. Kotloff, PI
National Institute of Allergy and Infectious Diseases HHSN27220080005C
11/2007 – 10/2014
Vaccine and Treatment Evaluation Units (VTEUs): Evaluation of control measures against diseases other than AIDS
Christopher V. Plowe, PI
US Agency for International Development AID-C-486-09-00004
10/2009 – 09/2012
Molecular surveillance of drug resistant malaria in the Greater Mekong Subregion
Federal Cooperative Agreements
Eileen M. Barry, PI
National Institute of Allergy and Infectious Diseases U01 AI077909
09/2009 – 08/2012
Advancement of new live attenuated F. tularensis type A vaccine strains
Miriam K. Laufer, PI
National Institute of Allergy and Infectious Diseases U01 AI087624
06/2010 – 05/2014
Clinical trial of chloroquine weekly or as IPT to prevent malaria in pregnancy in Malawi
Miriam K. Laufer, PI
National Institute of Allergy and Infectious Diseases U01 AI089342
08/2011 – 07/2015
Clinical trial of trimethoprim-sulfamethoxazole or chloroquine in adults on ART
Christopher V. Plowe, PI
National Institute of Allergy and Infectious Diseases U01 AI065683
07/2010 – 06/2015
Genetic diversity and protective immunity to malaria infection and disease
Marcelo B. Sztein, PI
National Institute of Allergy and Infectious Diseases U19 AI082655
06/2009 – 05/2014
CCHI: Mucosal immunity, vaccines and microbiota interplay in humans and animal models
Federal Grants
Alan S. Cross, PI
National Heart, Lung and Blood Institute R01 HL086933
08/2007 – 06/2012
Role of sialodase in pulmonary host defenses and acute lung injury
Myron M. Levine, PI
National Institute of Allergy and Infectious Diseases U54 AI057168
03/2009 – 02/2014
Middle Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MARCE 2)
Kirsten E. Lyke, PI
National Institute of Allergy and Infectious Diseases R01 AI067954
08/2008 – 07/2012
Immunologic determinants of Schistosoma-mediated resistance to malaria in humans
Marcela Pasetti, PI
National Institute of Allergy and Infectious Diseases R01 AI065760
02/2006 – 01/2013
Immune response to biodefense vaccines early in life
Marcela Passetti, PI
National Institute of Allergy and Infectious Diseases R01 AI089519
06/2010 – 05/2015
A.L. lactis-based vaccine for children with broad spectrum for enteric pathogens
Christopher V. Plowe, PI
National Institute of Allergy and Infectious Diseases R01 AI93635
02/2012 – 01/2016
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigen
Marcelo B. Sztein, PI
National Institute of Allergy and Infectious Diseases R01 AI036525
12/2006 – 11/2012
Immune mechanisms of protection in S. typhi vaccines
Sharon M. Tennant, PI
National Institute of Allergy and Infectious Diseases R21 AI100168
06/2012 – 05/2014
Rapid and sensitive detection of Salmonella from blood, food and feces
Federal Training Grants
Myron M. Levine, PI
National Institute of Allergy and Infectious Diseases T32 AI007524
07/2007 – 06/2012
Fellowship training program in vaccinology
Christopher V. Plowe, PI
Fogarty International Center D43 TW001589
08/2011 – 07/2016
Malaria research training in Mali
Non-Federal Grants and Contracts
Andrea A. Berry, PI
Novartis Vaccines V59P14E1
05/2010 – 05/2015
V59P14E1: A phase IIIb study to evaluate the persistence of antibody responses among children who recieved Novartis MenACWY conjugate vaccine
Andrea A. Berry, PI
Sanofi Pasteur M5102/CCT #0619-10
05/2011 – 05/2014
Safety and immunogenicity of QUADRACEL compared to DAPTACEL + IPOL as the fifth dose in children 4 to 6 years of age in US
Wilbur H. Chen, PI
LigoCyte Pharmaceuticals
01/2012 – 12/2013
Central safety monitor LigoCyte study LV03-105
Wilbur H. Chen, PI
PaxVax CCT #0822-12
05/2012 – 05/2013
A phase 1 randomized, double-blind placebo-controlled study to evaluate the safety and immunogenicity of the live oral cholera vaccine candidate PXVX0200 Vibrio cholera serotype O1 inaba CVD 103-HgR V
Alan S. Cross, PI
Atox Bio, Inc.
09/2011 – 09/2013
Determining the in vivo effects of AB103 on host cytokine expression in a mouse thigh model infected with Streptococcus pyogenes
Karen L. Kotloff, PI
Johns Hopkins University 2001146958
09/2010 – 09/2013
Pneumonia etiology research for child health
Miriam K. Laufer, PI
Pfizer, Inc. GA-0660-IA
10/2006 – 12/2012
Longitudinal study of chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquoneproguanil to treat malaria in children in Blantyre, Malawi
Miriam K. Laufer, PI
University of Maryland, Baltimore Foundation 2008042
08/2008 – 01/2013
The molecular epidemiology of malaria during pregnancy
Miriam K. Laufer, PI
Michigan State University 61-0860
07/2010 – 06/2012
Determinants of malaria disease in Malawi
Myron M. Levine, PI
PATH Vaccine Solutions GAT.1371-07839-CTA
10/2008 – 02/2013
Safety, immunogenicity and efficacy following experimental challenge of CVD 1208S
Myron M. Levine, PI
Bill and Melinda Gates Foundation OPP1002744
11/2009 – 12/2013
Efficacy of maternal immunization with influenza vaccine in preventing influenza in infants and mothers in Mali, West Africa
Myron M. Levine, PI
Bill and Melinda Gates Foundation OPP1033572
06/2011 – 05/2013
Diarrheal disease in infants and young children in developing countries (GEMS 1A)
Myron M. Levine, PI
JSI Washington & JSI Logistics Services
08/2011 – 08/2013
Universal immunization project (Ethiopia)
Myron M. Levine, PI
Bill and Melinda Gates Foundation OPP1039437
11/2011 – 03/2013
Ultra-fast and sensitive detection of typhoidal and non-typhoidal Salmonella in blood using microwave-accelerated metal-enhanced fluorescence
Myron M. Levine, PI
Wellcome Trust
04/2012 – 10/2016
Live oral and parenteral conjugate vaccines to prevent invasive non-typhoidal Salmonella infections in infants and young children in sub-Saharan Africa
Kirsten E. Lyke, PI
PATH Vaccine Solutions GAT.0888-11-05164-CTA
10/2010 – 12/2013
Safety, immunogenicity and efficacy against malaria in the sporozoite challenge model of one dose of Ad35.CS.01 malaria vaccine followed by two doses of malaria RTS, S/AS01B vaccine in healthy adults
Marcela Pasetti, PI
Oklahoma State University
05/2010 – 11/2012
Use of type III secretion system antigen in a novel vaccine against Shigella
Marcela Pasetti, PI
Mucosis BV
08/2010 – 03/2013
Immunogenicity of GEM-LcrV formulations in adult mice
Marcela Pasetti, PI
Millennium Pharmaceuticals, Inc.
08/2011 – 08/2012
Protocol C13013- phase 1, randomized, double-blinded, placebo controlled, single dose study in healthy subjects
Christopher V. Plowe, PI
Doris Duke Charitable Foundation 2006095
Doris Duke Distinguished Clinical Scientist Award
01/2007 – 12/2012
Genetic diversity and malaria vaccine efficacy
Christopher V. Plowe, PI
Arizona State University 09-015
05/2008 – 04/2013
A global comparative study of the evolution of antimalarial drug resistance
Christopher V. Plowe, PI
Chancellor, Masters and Scholars of the University of Oxford
01/2009 – 12/2012
Worldwide Antimalarial Resistance Network (WWARN)
Marcelo B. Sztein, PI
NanoBio Corporation
05/2011 – 05/2014
UMB-CVD-CMI NanoBio flu study
Marcelo B. Sztein, PI
Baylor Research Institute 41000411233
05/2012 – 04/2013
Deep proteomics to identify correlates of protection in Ty21a typhoid vaccines
Marcelo B. Sztein, PI
Baylor Research Institute 41000411231
05/2012 – 04/2013
IL-17A and multifunctional CD8+ T cells in immunity to dengue infection in humans
Milagritos D. Tapia, PI
PATH Vaccine Solutions GAT.0779-07058-CRT
12/2011 – 12/2013 MVP PsA-TT-007 infant study in Mali
Mark A. Travassos, PI
Burroughs Wellcome Fund
07/2010 – 06/2012
Postdoctoral fellowship in tropical infectious disease